Recent News

• 04.23.2025 - Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
• 04.23.2025 - Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
• 04.09.2025 - Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
• 04.09.2025 - Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
• 04.08.2025 - Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
• 04.08.2025 - Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
• 04.07.2025 - Needham 24th Annual Virtual Healthcare Conference
• 04.07.2025 - Needham 24th Annual Virtual Healthcare Conference
• 04.01.2025 - Recursion to Participate in Upcoming Investor Conference
• 04.01.2025 - Recursion to Participate in Upcoming Investor Conference

Recent Filings

• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.27.2025 - 144 Report of proposed sale of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2025 - 3 Initial statement of beneficial ownership of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2025 - 3 Initial statement of beneficial ownership of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities